Clinical Trials Sponsored by Destiny Pharma Plc

Total 351 results

Destiny Pharma Plc

Completed

Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection

Staphylococcal Infections | Surgical Site Infection

United States, Serbia, Georgia
Destiny Pharma Plc

Completed

Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)

Staphylococcal Infection

United Kingdom
Destiny Pharma Plc

Completed

Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects

Staphylococcus Aureus Infection

United Kingdom
R-Pharm
Covance; Cromos Pharma LLC

Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

COVID-19
Yuria-Pharm
Pharmaxi LLC

Completed

Epidemiological Study of the COVID-2019 in Participating Organizations.

Covid19

Ukraine
4D pharma plc

Completed

A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States, United Kingdom, Ireland
Verona Pharma plc

Completed

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

COPD

United States, United Kingdom
Verona Pharma plc

Completed

SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects

Chronic Obstructive Pulmonary Disorder | Inflammatory Disorder of the Respiratory Tract

United Kingdom
Redx Pharma Plc

Recruiting

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Colorectal Cancer

Korea, Republic of, Spain, United States, United Kingdom
Redx Pharma Plc

Active, not recruiting

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Cancer | Solid Tumor

United Kingdom
4D pharma plc

Withdrawn

Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma (AVENU)

Urothelial Carcinoma

United States
4D pharma plc

Withdrawn

A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19

COVID-19

United Kingdom
4D pharma plc

Completed

Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease

Crohn's Disease

United Kingdom
Verona Pharma plc

Completed

The Effects of RPL554 on Top of Standard COPD Reliever Medications

Chronic Obstructive Pulmonary Disease

United Kingdom
4D pharma plc

Terminated

A Study of MRx-4DP0004 in Asthma

Asthma

United States, United Kingdom
Herantis Pharma Plc.

Active, not recruiting

Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE) (AdeLE)

Secondary Lymphedema

Finland, Sweden
4D pharma plc

Terminated

A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

Pancreatic Cancer

United States
Herantis Pharma Plc.

Terminated

A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema

Secondary Lymphedema

Finland
Poolbeg Pharma plc

Completed

Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses

Influenza, Human

Netherlands
Verona Pharma plc

Completed

Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients

COPD

United Kingdom, Poland, Germany, Bulgaria, Czechia, Romania
Verona Pharma plc

Completed

The Effects of RPL554 in Addition to Tiotropium in COPD Patients

Chronic Obstructive Pulmonary Disease Moderate
Verona Pharma plc

Completed

Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients

Asthma

Sweden, United Kingdom
Herantis Pharma Plc.
Renishaw plc.

Completed

Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study

Brain Diseases | Nervous System Diseases | Parkinson Disease | Movement Disorders | Neuro-Degenerative Disease

Sweden, Finland
Herantis Pharma Plc.
Renishaw plc.

Completed

Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease

Brain Diseases | Nervous System Diseases | Parkinson Disease | Movement Disorders | Neurodegenerative Diseases

Sweden, Finland
Redx Pharma Plc
Merck Sharp & Dohme LLC

Completed

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86)

Advanced Solid Tumours

United Kingdom, Australia
4D pharma plc
Merck Sharp & Dohme LLC

Terminated

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Oncology

United States
Verona Pharma Inc

Completed

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

Coronavirus Infection | Covid-19 | SARS-CoV-2

United States
Renishaw
Herantis Pharma Plc.

Active, not recruiting

Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions

Brain Diseases | Nervous System Diseases | Parkinson Disease | Movement Disorders | Neuro-Degenerative Disease

Finland, Sweden
LEO Pharma
ICON plc

Completed

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults

Healthy Volunteers

Netherlands
PLx Pharma

Completed

Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

Gastroduodenal Ulceration

United States
PLx Pharma

Completed

Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.

Bioequivalence

United States
PLx Pharma

Completed

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

Diabetes Mellitus, Type 2

United States
PLx Pharma

Completed

Food-Effect Pharmacokinetic Study of PL2200

Healthy

United States
PLx Pharma

Completed

Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex

Bioequivalence
PLx Pharma

Completed

Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers

Upper Gastrointestinal Mucosal Damage

United States
PLx Pharma

Completed

Pharmacodynamic and Pharmacokinetic Study of PL-ASA

Healthy Volunteers

United States
PLx Pharma

Completed

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients (RITE)

Diabetes Mellitus, Type 2

United States
Redx Pharma Plc
Simbec Research

Recruiting

Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Fibrosis | IPF

Italy, Spain, United States, Belgium, United Kingdom, Austria, Czechia, Poland, Switzerland
Redx Pharma Plc
Simbec Research

Completed

A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

Liver Diseases | Fibrosis | Kidney Diseases | Inflammation | Idiopathic Pulmonary Fibrosis | Non-alcoholic Steatohepatitis

United Kingdom
Herantis Pharma Plc.
ORA, Inc.

Completed

Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

Dry Eye Syndrome

United States
1200 Pharma, LLC

Terminated

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Advanced Solid Tumor

United States
Valinor Pharma LLC

Active, not recruiting

Naloxegol US PMR CV Safety.

Opioid Induced Constipation

United States
PRM Pharma, LLC

Withdrawn

Effect of PRM-125 on Ambulatory Blood Pressure

Hypertension

United States
BHR Pharma, LLC

Terminated

Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue (4WARD)

Mammographic Breast Density

United States, Germany, Spain
Woerwag Pharma LLC

Completed

Milgamma® and Milgamma® Compositum Step-therapy in Patients With Acute Non-specific Low Back Pain Receiving Modern NSAID

Acute Non-specific Low Back Pain

Russian Federation
TesoRx Pharma, LLC

Terminated

A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males

Endocrine System Diseases | Gonadal Disorders | Hypogonadism | Hypogonadism, Male | Testosterone Deficiency

United States
TesoRx Pharma, LLC

Completed

Oral Testosterone for the Treatment of Hypogonadism in Males

Hypogonadism

United States
Midnight Pharma, LLC

Completed

Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users

Abuse Potential Study
Promius Pharma, LLC

Terminated

Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Onychomycosis

United States, Dominican Republic
Synerx Pharma, LLC

Completed

Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions

Healthy

3

Subscribe